Services

1. Lévi F., Boige V., Hebbar M., Smith D., Lepère C., Focan C., Karaboué A., Guimbaud R., Carvalho C., Tumolo S., Innominato P., Ajavon Y., Truant S., Castaing D., De Baere T., Kunstlinger F., Bouchahda M., Rougier P., Adam R., Ducreux M., onbehalf of all the trial investigators, and the Association Internationale pour la Recherche sur le Temps Biologique et la Chronothérapie (ARTBC International), Paul Brousse hospital, Villejuif, France. Conversion to resection ofliver metastases from colorectal cancer withhepatic artery infusion of combined chemotherapy and systemic cetuximab inmulticenter trial OPTILIV (NCT00852228). Submitted

2. Lévi F., Dugué P.A., Innominato P., Karaboué A., Dispersyn G., Parganiha A., Giacchetti S., Moreau T., Focan C., Waterhouse J., Spiegel D., on behalf of the ARTBC Chronotherapy Group: Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 2014 Oct; 31(8):891-900.

3. Roche V., Mohamad-Djafari A., Innominato P., Karaboué A., Gorbach A., Lévi F. : Thoracic surface temperature rhythm as a circadian biomarker for cancer chronotherapy. Chronobiol Int. 2014 Jan 7.

4. Ortiz-Tudela E., Iurisci I., Beau J., Karaboue A., Moreau T., Angeles Rol M., Madrid J.A., Lévi F, Innominato P.F.: The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2013 Nov 7. doi: 10.1002/ijc.28587. [Epub ahead of print].

5. Innominato P.F., Giacchetti S., Moreau T., Bjarnason G.A., Smaaland R., Focan C., Garufi C., Iacobelli S., Tampellini M., Tumolo S., Carvalho C., Karaboué A., Poncet A., Spiegel D., Lévi F., International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013 Jul 15; 119(14):2564-73.

6. Innominato P.F., Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S., Carvalho C., Karaboué A., Lévi F., ARTBC International Chronotherapy Group. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011 Aug; 28(7):586-600.

7. Scully C.G., Karaboué A., Liu W.M., Meyer J., Innominato P.F., Chon K.H., Gorbach A.M., Lévi F. Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients. Interface Focus. 2011 Feb 6;1:48-60..

8. Bouchahda M., Macarulla T., Liedo G., Lévi F., Elez M.E., Paule B., Karaboué A., Artru P., Tabernero J., Machover D., Innominato P., Goldschmidt E., Bonnet D., Ducreux M., Castagne V., Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol. 2011 Dec;28 Suppl 1:S253-8.

9. Lévi F., Karaboué A., Gorden L., Innominato P. F., Saffroy R.l, Giacchetti S., Hauteville D., Guettier C., Adam R., Bouchahda M.: Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother. Pharmacol., 2011, 67 (2): 339-348.

10. Bouchahda M., Karaboué A., Saffroy R., Innominato P., Gorden L., Guettier C., Adam R., Lévi F. : Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother. Pharmacol., 2010, 66 (3) : 605-609.

11. Bouchahda M., Macarulla T., Spano J.P., Bachet J.B., Lledo G., Andre T., Landi B., Tabernero J., Karaboué A., Domont J., Levi F., Rougier P. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008 Sep;67(3):255-62.

12. Lévi F., Focan C., Karaboué A., De la Valette V., Focan-Henrard D., Baron B., Kreutz F., Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35.

13. Lévi F., Karaboué A., De la Valette V., Benoît Baron, Giacchetti S., Brézault-Bonnet C., Jasmin C. Rôle du moment du pic d'une perfusion chronomodulée de chimiothérapie sur sa toxicité chez des patients atteints de cancer colorectal métastatique. Pathol Biol. 2007, 55 (3) : 214-215.